Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPH4336 in Combination With Endocrine Therapy in HR-positive, HER2-negative Breast Cancer Patients With Brain Metastases
NCT05872347Phase 2Recruiting
- Sponsor
- Shanghai Pharmaceuticals Holding Co Ltd
- Start
- Sep 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SPH4336 in breast cancer, sponsored by Shanghai Pharmaceuticals Holding Co Ltd. Started Sep 2023; status: recruiting.
02
Drugs
SPH4336
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05872347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05872347.